2022
DOI: 10.1007/s40261-022-01171-5
|View full text |Cite|
|
Sign up to set email alerts
|

Pharmacokinetics and Safety of Erenumab after a Single Subcutaneous Injection Dose in Healthy Chinese Subjects

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 28 publications
0
2
0
Order By: Relevance
“…Erenumab has an average peak serum concentration in humans of 70–160 nM, with little difference between males and females, or migraine diagnosis (de Hoon et al, 2018; Shen et al, 2022). At face‐value, erenumab could be present at sufficient concentrations to at least partially occupy AMY 1 receptors, and thus some of the clinical effects could be attributed to AMY 1 receptor antagonism.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Erenumab has an average peak serum concentration in humans of 70–160 nM, with little difference between males and females, or migraine diagnosis (de Hoon et al, 2018; Shen et al, 2022). At face‐value, erenumab could be present at sufficient concentrations to at least partially occupy AMY 1 receptors, and thus some of the clinical effects could be attributed to AMY 1 receptor antagonism.…”
Section: Discussionmentioning
confidence: 99%
“…(j-l) the same data as presented in (a)-(c); however, data have been refitted with the global Gaddum-Schild equation. CGRP receptor this is 8.56 (2.75 nM; HEK293S cells) or 8.93(1.18 nM, Cos7), while against αCGRP at the AMY 1 receptor this is 6.82 (151 nM; HEK293S cells) or 6.93 (117 nM; Cos7 cells).Erenumab has an average peak serum concentration in humans of 70-160 nM, with little difference between males and females, or migraine diagnosis(de Hoon et al, 2018;Shen et al, 2022). At facevalue, erenumab could be present at sufficient concentrations to at least partially occupy AMY 1 receptors, and thus some of the clinical effects could be attributed to AMY 1 receptor antagonism.…”
mentioning
confidence: 99%